View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 24, 2017

Samsung Bioepis receives FDA approval for Renflexis across all eligible indications

Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing Remicade (infliximab), Renflexis (infliximab-abda), across all eligible indications.

Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing Remicade (infliximab), Renflexis (infliximab-abda), across all eligible indications.

Renflexis is the first Samsung Bioepis product that received marketing approval in the US.

Renflexis is a tumour necrosis factor (TNF) blocker that has been indicated to reduce signs and symptoms in patients suffering from adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and also for treating adult plaque psoriasis.

Samsung Bioepis president and CEO Christopher HansungKo said: “Since our company was established five years ago, we have strived day in and day out to realise the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost.

“We hope this regulatory milestone will bring us a step closer to achieving this goal.

“Through relentless process innovation and an uncompromising commitment to quality, we remain committed to advancing one of the industry's strongest biosimilar pipelines.”

"We hope this regulatory milestone will bring us a step closer to achieving this goal."

Merck will market and distribute Renflexis in the US.

Samsung Bioepis’ infliximab is biosimilar to Renflexis, which has already been approved for marketing in 28 European Union (EU) member states, including Norway, Liechtenstein, Iceland, Australia and Korea.

Samsung Bioepis develops and manufactures all immunology and oncology bio-similar products, including Renflexis.

It also conducts global clinical trials and regulatory registration in all markets worldwide for these bio-similar candidates.


Image: Samsung Bioepis headquarters in Incheon, South Korea. Photo: courtesy of Business Wire.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology